$ABBV QuantLogix Newsdesk · June 13, 2026 at 1:32 PM UTC

Teva Biosimilar Expansion Adds Competitive Pressure on ABBV Portfolio

What happened

Teva Pharmaceutical is expanding its biosimilar pipeline, increasing competitive pressure on AbbVie's branded drug portfolio, particularly drugs facing biosimilar entry. Teva has positioned biosimilars as a core growth segment, with multiple adalimumab-class and other biologic copies advancing through its commercial lineup. AbbVie's Humira already faces a crowded biosimilar field following loss of exclusivity, and Teva's accelerating commitment to the category extends that competitive dynamic into additional AbbVie revenue lines.

The QL Read

QuantLogix's composite reading on ABBV stands at 57/100, with shares at $227.73, up 1.19% on the session. Watch whether biosimilar erosion rates disclosed in upcoming quarterly results pressure that composite below the 55 threshold.

Source: The Motley Fool — "Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?" — 2026-06-12T20:05:00Z

Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.